No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial)

Abstract Background Antiretroviral therapy (ART) in people with HIV (PWH) can lead to weight gain, but the effects of nucleoside reverse transcriptase inhibitors such as abacavir (ABC) are not well understood. In this study, we investigated whether discontinuing ABC would mitigate weight changes and...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Karen Brorup Heje, Magnus Søltoft Lindhardt, Alessandra Meddis, Andreas Knudsen, Gitte Kronborg, Nina Weis, Anne-Mette Lebech, Ole Kirk, Jannik Helweg-Larsen, Morten Helms, Christian Philip Fischer, Ann-Brit Eg Hansen, Søren Møller, Hartwig Roman Siebner, Jens Dahlgaard Hove, Jan Gerstoft, Thomas Benfield
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2025-09-01
coleção:	BMC Infectious Diseases
Assuntos:	HIV Antiretroviral therapy, highly active Abacavir Weight gain Body weight
Acesso em linha:	https://doi.org/10.1186/s12879-025-11334-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!